Immune-Mediated Colitis - Symptoms, Causes, Treatment & Prevention

```html

Overview

Immune‑mediated colitis is an inflammatory condition of the colon that results from an inappropriate immune response against the lining of the large intestine. It is most commonly seen as a side‑effect of immune checkpoint inhibitor (ICI) cancer therapies, but it can also arise in the setting of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, or after organ transplantation.

While the exact prevalence varies by cause, recent oncology data indicate that up to 5–10 % of patients receiving ICIs develop clinically significant colitis, with higher rates (≈15 %) reported for combination regimens (e.g., anti‑CTLA‑4 + anti‑PD‑1) [1] Mayo Clinic. In the broader population of inflammatory bowel disease (IBD), immune‑mediated colitis accounts for roughly 10‑15 % of cases [2] CDC. It can affect adults of any age, but the median age of onset for ICI‑related colitis is 58 years, and women appear slightly less often affected than men (≈40 % vs 60 %) [3] NCCN.

Symptoms

Symptoms can range from mild to severe and may develop suddenly (hours to days) after exposure to a triggering factor, or gradually over weeks. Common presentations include:

Gastrointestinal

• Diarrhea: ≥3 loose stools per day; may be watery or contain mucus.
• Abdominal pain or cramping: Often diffuse, may worsen after meals.
• Rectal bleeding: Fresh blood mixed with stool or on toilet paper.
• Urgency and incontinence: Sudden need to defecate, sometimes with loss of stool control.
• Nausea / vomiting: Particularly if inflammation extends proximally.
• Weight loss: Due to malabsorption and reduced intake.

Systemic

• Fever: Usually low‑grade (<38 °C) but may be higher if infection co‑exists.
• Fatigue: Common in chronic inflammation.
• Dehydration signs: Dry mouth, dizziness, decreased urine output.

Red‑flag features (suggest more severe disease)

• Bloody diarrhea >6 stools/24 h
• Severe abdominal pain with guarding or rebound tenderness
• High‑grade fever (>38.5 °C)
• Signs of perforation (sudden severe pain, rigid abdomen)
• Persistent vomiting preventing oral intake

Causes and Risk Factors

Immune‑mediated colitis is not caused by a single pathogen; instead, it results from dysregulated immune activation. The main categories are:

1. Immune Checkpoint Inhibitors (ICIs)

• Anti‑CTLA‑4 agents (e.g., ipilimumab) – highest colitis rates.
• Anti‑PD‑1/PD‑L1 agents (e.g., nivolumab, pembrolizumab) – lower but still significant rates.
• Combination therapy sharply raises risk (up to 15 %).

2. Primary Autoimmune Disorders

• Rheumatoid arthritis, systemic lupus erythematosus, primary sclerosing cholangitis.

3. Other Medications

• High‑dose steroids (paradoxically can trigger flare when tapered), certain antibiotics (e.g., clindamycin) that alter gut microbiota.

4. Genetic and Environmental Factors

• HLA‑DRB1*04 variants linked to higher ICI‑colitis risk [4] JAMA Oncology.
• Smoking, a Western diet high in fat/sugar, and prior antibiotic exposure may predispose by altering gut microbiome.

Risk Summary

• Receiving combination ICI therapy
• History of autoimmune disease
• Female sex (slightly lower risk but higher severity when it occurs)
• Older age (>65 y) for ICI‑related colitis
• Pre‑existing gut dysbiosis (e.g., after recent antibiotics)

Diagnosis

Diagnosis is a stepwise process that aims to confirm inflammation, exclude infection, and determine severity.

Clinical Evaluation

• Detailed history (oncologic therapy timeline, autoimmune background, medication list).
• Physical exam focusing on abdomen (tenderness, distension) and signs of dehydration.

Laboratory Tests

• Complete blood count (CBC) – look for anemia, leukocytosis.
• Comprehensive metabolic panel – assesses electrolytes and renal function.
• C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) – markers of inflammation.
• Stool studies: culture, ova & parasites, Clostridioides difficile toxin PCR to rule out infectious colitis.

Imaging

• Abdominal CT scan (contrast‑enhanced) – detects wall thickening, edema, and complications (e.g., perforation).
• Ultrasound may be used in pregnant patients.

Endoscopic Assessment

• Colonoscopy with biopsies is the gold standard.
• Typical endoscopic findings: diffuse erythema, loss of vascular pattern, ulcerations, and pseudomembranes.
• Histology shows crypt abscesses, neutrophilic infiltration, and lamina propria expansion.

Scoring Severity

Several scoring systems are used; the most common for ICI‑colitis is the CTCAE (Common Terminology Criteria for Adverse Events) v5.0, which grades diarrhea/colitis from 1 (mild) to 5 (death).

Treatment Options

Therapy is individualized based on severity, underlying cause, and patient comorbidities.

1. Supportive Care (All grades)

• Oral rehydration solutions or IV fluids for moderate‑to‑severe dehydration.
• Electrolyte replacement (especially potassium and magnesium).
• Dietary modifications – low‑residue, bland diet (e.g., rice, bananas, broth).

2. Pharmacologic Therapy

• Corticosteroids – First‑line for grade ≥2 colitis.
  • Prednisone 1 mg/kg/day PO or methylprednisolone 1‑2 mg/kg IV if unable to tolerate oral intake.
  • Taper over 4–6 weeks to prevent rebound.
• Biologic agents – For steroid‑refractory or steroid‑dependent disease.
  • Infliximab (anti‑TNFα) 5 mg/kg IV at weeks 0, 2, 6 (may repeat).
  • Vedolizumab (α4β7 integrin blocker) – gut‑selective, useful when anti‑TNF risks are high.
  • Emerging data support abatacept (CTLA‑4‑Ig) in select ICI‑colitis patients.
• Immunomodulators – Azathioprine or 6‑mercaptopurine are rarely used due to slower onset.
• Antibiotics – Only if secondary infection (e.g., C. difficile) is proven.

3. Procedural Interventions

• Endoscopic hemostasis for active bleeding.
• Surgical resection (colectomy) is a last resort for perforation, uncontrolled hemorrhage, or refractory disease despite maximal medical therapy (≈1–2 % of cases) [5] Cleveland Clinic.

4. Adjusting Cancer Therapy (if applicable)

When colitis is linked to ICIs, oncologists may hold or discontinue the checkpoint inhibitor. Re‑challenge is possible after complete resolution and may be done with prophylactic steroids or biologics in high‑risk patients.

Living with Immune‑Mediated Colitis

Long‑term management focuses on symptom control, preventing flares, and maintaining nutritional status.

Daily Lifestyle Tips

• Hydration: Aim for ≥2 L of clear fluids daily; use oral rehydration salts if diarrhea is frequent.
• Diet: Low‑fiber, low‑fat, and low‑spice foods during active disease; gradually re‑introduce fiber (soluble oats, applesauce) after remission.
• Probiotics: Strains such as F. prausnitzii and L. rhamnosus GG have modest evidence for reducing mild flare frequency [6] NIH.
• Exercise: Light to moderate activity (walking, yoga) improves GI motility and mood.
• Stress management: Mindfulness, CBT, or meditation can lessen symptom perception.
• Medication adherence: Never stop steroids or biologics abruptly; follow taper schedules.
• Regular follow‑up: Every 3–6 months for colonoscopic surveillance, especially if chronic inflammation persists.

Monitoring Tools

• Stool diaries to track frequency, consistency (Bristol Stool Chart), and blood presence.
• Home CRP kits (available commercially) can give an early signal of inflammation.
• Periodic blood work: CBC, electrolytes, liver function (especially if on azathioprine).

Prevention

Because many cases are treatment‑related, prevention strategies aim at risk mitigation before and during therapy.

• Pre‑treatment screening: Identify pre‑existing autoimmune disease, baseline colonoscopy if high risk.
• Microbiome stewardship: Avoid unnecessary antibiotics; consider probiotic or fecal microbiota transplantation (FMT) in clinical trials for high‑risk patients.
• Gradual dose escalation: When possible, start with lower ICI doses and monitor.
• Prophylactic steroids/biologics: Small studies suggest low‑dose prednisone (≤10 mg/day) during combination ICI therapy reduces severe colitis incidence without compromising cancer response [7] Lancet Oncology.
• Vaccinations: Keep up to date (influenza, COVID‑19, pneumococcal) to prevent infections that could mimic or exacerbate colitis.

Complications

If left uncontrolled, immune‑mediated colitis can lead to serious sequelae:

• Colonic perforation: Life‑threatening; may require emergent surgery.
• Severe hemorrhage: Chronic ulceration can cause anemia and transfusion dependence.
• Chronic strictures: Fibrosis leading to obstructive symptoms.
• Malnutrition and electrolyte imbalance: Particularly in prolonged diarrhea.
• Increased infection risk: Immunosuppressive therapy predisposes to opportunistic infections (e.g., CMV colitis).
• Impact on cancer outcomes: In some studies, severe colitis correlates with better anti‑tumor response, but treatment interruptions can compromise overall survival [8] JCO.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. Immune checkpoint inhibitor–related colitis: Incidence & management. 2022.
2. Centers for Disease Control and Prevention. Inflammatory bowel disease overview. 2023.
3. National Comprehensive Cancer Network (NCCN). Guidelines for management of immune‑related adverse events. Version 2.2024.
4. JAMA Oncology. HLA‑DRB1*04 association with ICI‑colitis. 2021;7(5):721‑730.
5. Cleveland Clinic. Surgical considerations in refractory colitis. 2020.
6. National Institutes of Health. Probiotics in IBD: A systematic review. 2022.
7. Lancet Oncology. Low‑dose prednisone prophylaxis during combination ICI therapy. 2023.
8. Journal of Clinical Oncology. Correlation of immune‑related colitis severity with tumor response. 2024.

```